Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382038 | 0.89 | RIPK1 (0.37) | LMNARIPK1CACNA1FCHRM2CHRM1 | |
| SCHEMBL4378296 | 0.86 | TACR1 (0.34) | SMN1; SMN2RIPK1CACNA1FCHRM2CHRM1 | |
| SCHEMBL4371869 | 0.85 | RIPK1 (0.36) | SMN1; SMN2LMNAHTTTSHRALOX12 | |
| SCHEMBL4379662 | 0.83 | RIPK1 (0.35) | LMNATSHRRIPK1CACNA1FCHRM2 | |
| SCHEMBL4367346 | 0.82 | LMNA (0.36) | SMN1; SMN2LMNAHTTTSHRALOX12 | |
| SCHEMBL4376388 | 0.81 | RIPK1 (0.37) | SMN1; SMN2LMNAHTTRIPK1MEN1 | |
| SCHEMBL4379459 | 0.79 | RIPK1 (0.38) | SMN1; SMN2LMNAHTTRIPK1MEN1 | |
| SCHEMBL4369917 | 0.78 | HTT (0.36) | SMN1; SMN2LMNAHTTTSHRALOX12 | |
| SCHEMBL4380919 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAHTTTSHRALOX12 | |
| SCHEMBL4375502 | 0.76 | HTT (0.34) | SMN1; SMN2LMNAHTTTSHRALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1323724-B1 | Ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6790973-B2 | REDUCTION OF KETONE TO ALCOHOL USING COMPLEX CATALYST | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1323724-A2 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | SMN1; SMN2 4694/4885LMNA 3915/4885HTT 2539/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | SMN1; SMN2 3025/4885LMNA 4608/4885HTT 4105/4885 |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | ADH1C, ADH1A, ADH5 | SMN1; SMN2 4684/4885LMNA 4207/4885HTT 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.